What Are the Latest Advances in 2025 for HER2 Metastatic Breast Cancer and Genital Plastic Surgery in the USA?

This article outlines HER2 metastatic breast cancer treatments and current genital plastic surgery options in 2025, providing key recommendations, eligibility criteria, and patient pathways informed by the latest guidelines and clinical consensus.

Advanced Treatments for HER2-Positive Metastatic Breast Cancer in 2025

First-Line Standard of Care

For patients newly diagnosed with HER2-positive metastatic breast cancer (mBC), the primary first-line regimen combines dual anti-HER2 monoclonal antibodies—trastuzumab and pertuzumab—with a taxane chemotherapy agent (such as docetaxel or paclitaxel). This triplet therapy is a standard approach in the USA and Europe, based on published treatment guidelines and studies [1] [2].

Eligibility:

• Confirmed HER2-positive mBC by immunohistochemistry and/or in situ hybridization
• Adequate organ function and performance status
• Comorbidities should be managed to allow treatment

Next-Line and Later Therapies: Antibody-Drug Conjugates (ADCs)

For disease progression after first-line therapy, current 2025 guidelines recommend antibody-drug conjugates:

• Trastuzumab deruxtecan (T-DXd, Enhertu®) is preferred in many second-line settings based on clinical evidence.
• Trastuzumab emtansine (T-DM1, Kadcyla®) remains an available and widely used option.

Selection is guided by:

• Previously used therapies
• Patient tolerance and any prior side effects
• Presence or absence of brain metastases (T-DXd has demonstrated activity in some central nervous system studies)

These ADCs link chemotherapy to HER2 antibodies for targeted delivery.

Novel and Clinical Trial Therapies

In 2025, clinical trials in the USA evaluate:

• HER2 bispecific antibodies
• HER2-targeted CAR-T cell therapies

Genomic and germline testing (e.g., BRCA1/2, PALB2) is recommended for assessing eligibility for certain approved or investigational agents, such as PARP inhibitors (for specific genetic subtypes) and matching to clinical trials.

Clinical trials may provide:

• Early access to investigational treatments
• Supportive care and frequent monitoring at specialized centers

Role of Immunotherapy

Immunotherapy (checkpoint inhibitors) is generally investigational for HER2-positive mBC as of 2025, based on current evidence. It is used more commonly in other breast cancer subtypes.

Supportive, Surgical, and Oncoplastic Care

Surgical and oncoplastic options are used in certain metastatic cases—for symptom management or isolated metastasis—based on individual scenarios. Reconstructive surgery options (such as prepectoral implants, tissue flaps, and fat grafting) remain available, with specialized teams coordinating care, including for those with prior therapies.

Pathways for Other Breast Cancer Subtypes

Triple Negative Breast Cancer (TNBC)

For triple negative metastatic breast cancer (ER-/PR-/HER2-), immunotherapy (checkpoint inhibitors like pembrolizumab or atezolizumab) in combination with chemotherapy is considered if the tumor is PD-L1 positive. For PD-L1-negative disease, standard chemotherapy regimens or clinical trials are recommended.

Hormone Receptor Positive / HER2-Negative (HR+/HER2-) mBC

For patients with HR+/HER2− mBC:

• CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) with endocrine therapy (aromatase inhibitors or fulvestrant) are used first.
• If PIK3CA mutation is present, alpelisib may be added.
• Tumors with ESR1 mutations can be treated with oral SERDs (such as elacestrant).

These treatment combinations reflect widely accepted approaches in US cancer centers.

Hormonal Therapy

Endocrine therapy remains integral for hormone receptor-positive breast cancers. Recent therapies (including new oral SERDs, CDK4/6 inhibitors, and PI3K-directed agents) are selected based on the tumor’s molecular features and prior treatments.

Options and Considerations in Genital Plastic Surgery

Overview of Genital Plastic Surgery in 2025

Genital plastic surgery in the USA includes:

• Gender-affirming surgeries (such as vaginoplasty, phalloplasty, vulvoplasty, metoidioplasty, labiaplasty) for transgender and non-binary people
• Reconstructive procedures for congenital, injury-related, or post-cancer needs

Specialty centers with expertise in plastic, urologic, and gynecologic surgery provide these services.

Patient Selection and Preparation

• Multidisciplinary evaluation: Involvement of surgeons, mental health providers, and primary care to assess readiness, review risks/benefits, and plan postoperative care
• Requirements: Stable health, understanding of procedure goals, ability to adhere to aftercare, documentation of gender dysphoria (when indicated) and usually adherence to WPATH Standards of Care
• Insurance and Costs: Coverage varies; some US insurers cover medically necessary procedures, but patients are encouraged to confirm coverage and authorization requirements with their providers. Self-pay is available when insurance does not apply.

Breast Cancer in Transgender Populations

Transgender individuals may have specific risk profiles and can access both chest masculinization (mastectomy) and augmentation procedures. Screening and genetic counseling are advised in accordance with guidelines, emphasizing the importance of affirming, specialized care environments.

Costs and Access

• HER2 mBC Treatments: Many insurance plans include targeted therapies, though out-of-pocket costs may vary. Assistance programs and clinical trial options may help address financial concerns.
• Genital Plastic Surgery: Costs for procedures may range from $5,000 to more than $50,000, depending on the operation and setting. Insurance coverage, especially for reconstructive and gender-affirming surgeries, is becoming more common. Patients should discuss specific billing and coverage details with their providers and insurers.

Key Points and Guidance for Patients in 2025

• Standard first-line treatment for HER2 mBC typically includes a trastuzumab/pertuzumab/taxane combination. Trastuzumab deruxtecan and trastuzumab emtansine are commonly used in subsequent treatment lines.
• Participation in clinical trials offers access to novel HER2 therapies and supportive care.
• Comprehensive genomic profiling helps guide personalized therapy and eligibility for certain treatments or studies.
• Genital plastic surgery is available through specialized teams nationwide, supporting both reconstructive and gender-affirming needs.
• Early engagement with financial counselors and insurance representatives can clarify coverage and assist with planning treatment or surgery.
• Multidisciplinary care, provided by academic centers and dedicated surgical facilities, supports informed decision-making and coordinated care.

For information about adult incontinence protection, patients are advised to consult with specialty urology professionals or product providers, as this topic is outside the scope of this article.

Sources

1. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025
2. Breast Cancer Treatment (PDQ®)–Health Professional Version (NCI)
3. Moffitt Cancer Center – Reconstructive Oncology and Microsurgery Fellowship

Disclaimer: All content, including text, graphics, images and information, contained on or available through this web site is for general information purposes only. The information and materials contained in these pages and the terms, conditions and descriptions that appear, are subject to change without notice.